Patent ID: 8895065

Claim:
An oral single unit dose pharmaceutical composition in the form of a bilayered tablet comprising a) levodopa or salts thereof for extended release, b) carbidopa or salts thereof for extended release, and c) entacapone or salts thereof for immediate release, wherein a) and b) form a first layer of the tablet for extended release comprising levodopa at about 19.22 (% w/w), carbidopa at about 5.19 (% w/w), microcrystalline cellulose at 4.62 (% w/w) povidone at 3.46 (% w/w), and purified water (q.s.) based on the total weight of the tablet; and wherein c) forms a second layer of the tablet for immediate release comprising entacapone at about 30.77 (% w/w), mannitol 25 at 5.38 (% w/w), sodium starch glycolate at 4.62 (% w/w), croscarmellose sodium at 3.69 (% w/w), corn starch at 7.54 (% w/w), povidone K30 at 1.23 (% w/w), and magnesium stearate at 0.62 (% w/w), based on the total weight of the tablet.